SG11201402144WA - Improved modulators of hec1 activity and methods therefor - Google Patents

Improved modulators of hec1 activity and methods therefor

Info

Publication number
SG11201402144WA
SG11201402144WA SG11201402144WA SG11201402144WA SG11201402144WA SG 11201402144W A SG11201402144W A SG 11201402144WA SG 11201402144W A SG11201402144W A SG 11201402144WA SG 11201402144W A SG11201402144W A SG 11201402144WA SG 11201402144W A SG11201402144W A SG 11201402144WA
Authority
SG
Singapore
Prior art keywords
methods therefor
improved modulators
hec1
activity
hec1 activity
Prior art date
Application number
SG11201402144WA
Inventor
Yu-Ling Huang
Shih-Hsien Chuang
Ying-Shuan Eda Lee
Jiann-Jyh Huang
Johnson Lau
Original Assignee
Taivex Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taivex Therapeutics Corp filed Critical Taivex Therapeutics Corp
Publication of SG11201402144WA publication Critical patent/SG11201402144WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201402144WA 2011-11-29 2012-11-29 Improved modulators of hec1 activity and methods therefor SG11201402144WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161564773P 2011-11-29 2011-11-29
PCT/US2012/067132 WO2013082324A1 (en) 2011-11-29 2012-11-29 Improved modulators of hec1 activity and methods therefor

Publications (1)

Publication Number Publication Date
SG11201402144WA true SG11201402144WA (en) 2014-09-26

Family

ID=48536070

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201402144WA SG11201402144WA (en) 2011-11-29 2012-11-29 Improved modulators of hec1 activity and methods therefor

Country Status (12)

Country Link
US (2) US8999983B2 (en)
EP (1) EP2785714B1 (en)
JP (1) JP5970554B2 (en)
KR (1) KR101983585B1 (en)
CN (1) CN104254534B (en)
AU (1) AU2012345843B2 (en)
ES (1) ES2712134T3 (en)
HK (1) HK1202870A1 (en)
MX (1) MX371378B (en)
SG (1) SG11201402144WA (en)
TW (1) TWI640519B (en)
WO (1) WO2013082324A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071736B2 (en) * 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor
NZ739834A (en) 2012-10-02 2018-11-30 Bayer Cropscience Ag Heterocyclic compounds as pesticides
EP3066092B1 (en) * 2013-11-06 2018-09-05 Bristol-Myers Squibb Company Substituted pyridine derivatives useful as gsk-3 inhibitors
EP3146078B1 (en) * 2014-05-17 2019-11-27 The Regents of the University of California Centromere/kinetochore protein genes as markers for cancer diagnosis and prognosis and for treatment selection
EP3758700B1 (en) 2018-02-28 2024-07-31 University of Southern California Compositions for modulating inflammatory and degenerative disorders
TWI750905B (en) * 2020-11-19 2021-12-21 財團法人國家衛生研究院 Thiazole compounds as protein kinase inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0228175A (en) * 1987-12-14 1990-01-30 Sawai Seiyaku Kk Carboxamide derivative containing thiazole ring and tetrazole ring and use thereof
US6043246A (en) * 1996-12-03 2000-03-28 Banyu Pharmaceutical Co., Ltd. Urea derivatives
CN1376150A (en) * 1999-07-26 2002-10-23 盐野义制药株式会社 Drug compositions exhibiting thrombo poietin agonism
AU7950100A (en) * 1999-10-22 2001-05-08 Takeda Chemical Industries Ltd. 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof
AU2003250831A1 (en) 2002-06-12 2003-12-31 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of hec1 antagonists in the treatment of proliferative disorders and cancer
WO2004033666A2 (en) * 2002-10-11 2004-04-22 Board Of Regents, The University Of Texas System Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
JP2007504255A (en) 2003-09-06 2007-03-01 バーテックス　ファーマシューティカルズ　インコーポレイテッド Regulators of ATP-binding cassette transporters
WO2005040135A1 (en) * 2003-10-24 2005-05-06 Ono Pharmaceutical Co., Ltd. Antistress drug and medical use thereof
EP1682538A4 (en) * 2003-10-27 2009-05-27 S Bio Pte Ltd Biaryl linked hydroxamates: preparation and pharmaceutical applications
EP3219709B1 (en) * 2004-01-30 2020-03-18 Vertex Pharmaceuticals Incorporated Intermediate compound of modulators of atp-binding cassette transporters
WO2006136823A1 (en) * 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
WO2007004038A1 (en) 2005-07-05 2007-01-11 Pfizer Products Inc. Aminothiazole derivatives as agonists of the thrombopoietin receptor
WO2007008541A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
CN102775396B (en) * 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Modulators of ATP-binding cassette transporters
RU2008128453A (en) * 2005-12-12 2010-01-20 Дженелабс Текнолоджис, Инк. (Us) COMPOUND OF N- (5-MEMORY ARIL) AMIDES, PHARMACEUTICAL COMPOSITION WITH ANTIVIRAL ACTIVITY BASED ON THEM, METHOD FOR TREATING OR PREVENTING VIRAL INFECTION WITH THEIR HELP AND METHOD
WO2007131071A2 (en) 2006-05-02 2007-11-15 Washington State University Mig-7 as a specific anticancer target
WO2009091813A1 (en) * 2008-01-14 2009-07-23 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
WO2009140519A1 (en) * 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
WO2009144548A1 (en) * 2008-05-28 2009-12-03 Glenmark Pharmaceuticals S.A. Imidazo [2,1-b] purine derivatives as trpa1 modulators
US20120046305A1 (en) * 2008-09-24 2012-02-23 Moran Magdalene M Methods and compositions for treating respiratory disorders
US8324385B2 (en) 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
KR20120001746A (en) * 2009-03-23 2012-01-04 그렌마크 파머수티칼스 에스. 아. Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
DE102009014484A1 (en) * 2009-03-23 2010-09-30 Bayer Schering Pharma Aktiengesellschaft Substituted piperidines
EP2309273B1 (en) 2009-09-16 2016-05-18 ZEILLINGER, Robert Novel tumor marker determination
CN105906617B (en) 2010-03-17 2018-09-04 泰纬生命科技股份有限公司 HEC1 active regulators and its method
JP6099662B2 (en) * 2011-11-21 2017-03-22 タイヴェックス・セラピューティクス・コーポレイションＴａｉｖｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏｒｐｏｒａｔｉｏｎ Cancer biomarkers responsive to modulators of HEC1 activity

Also Published As

Publication number Publication date
NZ624552A (en) 2015-06-26
CN104254534A (en) 2014-12-31
MX2014006157A (en) 2015-04-08
CN104254534B (en) 2017-07-14
KR20140138596A (en) 2014-12-04
EP2785714A4 (en) 2015-09-09
US20130190312A1 (en) 2013-07-25
US8999983B2 (en) 2015-04-07
US20150250794A1 (en) 2015-09-10
TW201326164A (en) 2013-07-01
ES2712134T3 (en) 2019-05-09
TWI640519B (en) 2018-11-11
AU2012345843B2 (en) 2017-11-23
US10588909B2 (en) 2020-03-17
MX371378B (en) 2020-01-28
EP2785714A1 (en) 2014-10-08
JP2014534271A (en) 2014-12-18
AU2012345843A1 (en) 2014-05-29
WO2013082324A1 (en) 2013-06-06
KR101983585B1 (en) 2019-05-29
HK1202870A1 (en) 2015-10-09
JP5970554B2 (en) 2016-08-17
EP2785714B1 (en) 2018-11-21

Similar Documents

Publication Publication Date Title
IL263020A (en) Novel modulators and methods of use
IL247595A0 (en) Novel modulators and methods of use
HK1215284A1 (en) Site-specific enzymes and methods of use
GB2488674B (en) Catalyst and method of preparation
HK1176055A1 (en) Modulators of hec1 activity and methods therefor hec1
EP2672820A4 (en) Mannoside compounds and methods of use thereof
IL227333A0 (en) Methods for prepar5iaon of glycosphingolipids and uses thereof
SG10201601792UA (en) Novel modulators and methods of use
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
SG10201506782XA (en) Notum protein modulators and methods of use
EP2665486A4 (en) Compositions and mehthods for modulating gamma-c-cytokine activity
HK1202870A1 (en) Improved modulators of hec1 activity and methods therefor hec1
EP2852397A4 (en) Huwentoxin-iv variants and methods of use
EP2726218A4 (en) Adhesive complex coacervates and methods of making and using thereof
EP2763962A4 (en) Methods of treatment using modulators of sirt2
EP2709999A4 (en) Quinazoline-7-ether compounds and methods of use
EP2670245A4 (en) Alpha-ketoheterocycles and methods of making and using
EP2753359A4 (en) Serpinf2-binding molecules and methods of use
AP2013007019A0 (en) Gaming system and method of use
EP2782670A4 (en) Coper-zicornia catalyst and method of use and manufacture
EP2898044A4 (en) Solid hydrogel media and methods of preparation and use therefor
EP2691420A4 (en) Modulators of plexin b2 activity
GB2516380B (en) Catalyst and method of preparation
GB201416065D0 (en) Catalysts and methods of making and using catalysts
AU2011901049A0 (en) Catalysts and Methods of Use